Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia

被引：0
|
作者：
Elena Ceccacci
Saverio Minucci
机构：
[1] European Institute of Oncology,Department of Experimental Oncology and Drug Development Program
[2] University of Milan,Department of Biosciences
来源：
British Journal of Cancer | 2016年 / 114卷
关键词：
leukaemia; histone deacetylases; HDACi; cancer stem cells; APL; epigenetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Histone deacetylases (HDACs) are a key component of the epigenetic machinery regulating gene expression, and behave as oncogenes in several cancer types, spurring the development of HDAC inhibitors (HDACi) as anticancer drugs. This review discusses new results regarding the role of HDACs in cancer and the effect of HDACi on tumour cells, focusing on haematological malignancies, particularly acute myeloid leukaemia. Histone deacetylases may have opposite roles at different stages of tumour progression and in different tumour cell sub-populations (cancer stem cells), highlighting the importance of investigating these aspects for further improving the clinical use of HDACi in treating cancer.
引用
收藏
页码：605 / 611
页数：6
相关论文
共 50 条
  • [21] Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy
    S Spiegel
    S Milstien
    S Grant
    Oncogene, 2012, 31 : 537 - 551
  • [22] Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy
    Spiegel, S.
    Milstien, S.
    Grant, S.
    ONCOGENE, 2012, 31 (05) : 537 - 551
  • [23] Inhibition of histone deacetylases in melanomaa perspective from bench to bedside
    Hornig, Eva
    Heppt, Markus V.
    Graf, Saskia A.
    Ruzicka, Thomas
    Berking, Carola
    EXPERIMENTAL DERMATOLOGY, 2016, 25 (11) : 831 - 838
  • [24] Histone deacetylases and transcriptional therapy with their inhibitors
    Pandolfi, PP
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (Suppl 1) : S17 - S19
  • [25] Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy
    Laschanzky, Richard S.
    Humphrey, Lisa E.
    Ma, Jihyun
    Smith, Lynette M.
    Enke, Thomas J.
    Shukla, Surendra K.
    Dasgupta, Aneesha
    Singh, Pankaj K.
    Howell, Gillian M.
    Brattain, Michael G.
    Ly, Quan P.
    Black, Adrian R.
    Black, Jennifer D.
    CANCERS, 2019, 11 (09)
  • [26] Histone deacetylases and transcriptional therapy with their inhibitors
    Pier Pandolfi
    Cancer Chemotherapy and Pharmacology, 2001, 48 : S17 - S19
  • [27] Selective inhibition of mutant histone deacetylases.
    Hedglin, M
    Ulrich, SM
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U492 - U492
  • [28] Inhibition of Histone Deacetylases in Inflammatory Bowel Diseases
    Glauben, Rainer
    Siegmund, Britta
    MOLECULAR MEDICINE, 2011, 17 (5-6) : 426 - 433
  • [29] The Structure and Function of Histone Deacetylases: The Target for Anti-cancer Therapy
    Zhang, Yingjie
    Fang, Hao
    Jiao, Jie
    Xu, Wenfang
    CURRENT MEDICINAL CHEMISTRY, 2008, 15 (27) : 2840 - 2849
  • [30] Innovative Strategies for Selective Inhibition of Histone Deacetylases
    Maolanon, Alex R.
    Madsen, Andreas S.
    Olsen, Christian A.
    CELL CHEMICAL BIOLOGY, 2016, 23 (07): : 759 - 768
12345